Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on May 16, 2013, involving a connected person of Director Sir Andrew Witty:
- Transfer of 670 Ordinary Shares from a nominee holding.
- Repurchase of 664 Ordinary Shares into an Individual Savings Account (ISA).
- Transaction prices were 1723.58p and 1723.64p per share, respectively.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the total shareholding of Sir Andrew Witty's connected person following the May 16, 2013 transactions.
- Confirm the compliance of the transaction with Disclosure Rule 3.1.4R(1)(a) and (c).
- Review the company's broader financial reports (e.g., Form 20-F) for performance metrics not included in this filing.